Emergent Enters Into a New CDMO Agreement with Providence Therapeutics to Provide Fill/Finish Drug Product Manufacturing

Feb 12, 2021 2:00:00 PM

Emergent has entered into a new CDMO agreement with Providence Therapeutics to provide fill/finish drug product manufacturing services for their investigational mRNA vaccine candidate (PTX-COVID19-B) at its facility in Winnipeg, Manitoba, Canada. This is Emergent's 8th COVID-19 CDMO collaboration, and first outside of the U.S. in Canada.

We are proud to harness our industry-leading portfolio of CDMO services to support pharma & biotech innovators and governments/NGOs.

Topics: COVID-19 news
Catherine Hanley

Written by Catherine Hanley

Vice President, Marketing & Customer Experience